Literature DB >> 21528051

Role of conventional therapies in the era of biological treatment in Crohn's disease.

Paolo Gionchetti1, Carlo Calabrese, Rosy Tambasco, Ramona Brugnera, Giulia Straforini, Giuseppina Liguori, Giulia Spuri Fornarini, Donatella Riso, Massimo Campieri, Fernando Rizzello.   

Abstract

Outstanding progress regarding the pathophysiology of Crohn's disease (CD) has led to the development of innovative therapeutic concepts. Numerous controlled trials have been performed in CD. This review concentrates on the results of randomized, placebo-controlled trials, and meta-analyses when available, that provide the highest degree of evidence. Current guidelines on the management of CD recommend a step-up approach to treatment involving the addition of more powerful therapies as the severity of disease and refractoriness to therapy increase. The advent of biological drugs has opened new therapeutic horizons for treating CD, modifying the treatment goals. However, the large majority of patients with CD will be managed through conventional therapy, even if they are a prelude to biological therapy.

Entities:  

Keywords:  5-Aminosalicylic acid; 6-Mercaptopurine; Anti-tumor necrosis facto-α; Azathioprine; Biological therapies; Crohn’s disease; Sulfasalazine

Mesh:

Substances:

Year:  2011        PMID: 21528051      PMCID: PMC3080713          DOI: 10.3748/wjg.v17.i14.1797

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  85 in total

1.  Disease activity courses in a regional cohort of Crohn's disease patients.

Authors:  P Munkholm; E Langholz; M Davidsen; V Binder
Journal:  Scand J Gastroenterol       Date:  1995-07       Impact factor: 2.423

2.  Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection.

Authors:  P Rutgeerts; M Hiele; K Geboes; M Peeters; F Penninckx; R Aerts; R Kerremans
Journal:  Gastroenterology       Date:  1995-06       Impact factor: 22.682

3.  A controlled double blind study of azathioprine in the management of Crohn's disease.

Authors:  S Candy; J Wright; M Gerber; G Adams; M Gerig; R Goodman
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

4.  Smoking habits and recurrence in Crohn's disease.

Authors:  M Cottone; M Rosselli; A Orlando; L Oliva; A Puleo; M Cappello; M Traina; F Tonelli; L Pagliaro
Journal:  Gastroenterology       Date:  1994-03       Impact factor: 22.682

5.  A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis.

Authors:  W J Tremaine; K W Schroeder; J M Harrison; A R Zinsmeister
Journal:  J Clin Gastroenterol       Date:  1994-12       Impact factor: 3.062

6.  Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

Authors:  Y Bouhnik; M Lémann; J Y Mary; G Scemama; R Taï; C Matuchansky; R Modigliani; J C Rambaud
Journal:  Lancet       Date:  1996-01-27       Impact factor: 79.321

7.  Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.

Authors:  B G Feagan; J Rochon; R N Fedorak; E J Irvine; G Wild; L Sutherland; A H Steinhart; G R Greenberg; R Gillies; M Hopkins
Journal:  N Engl J Med       Date:  1995-02-02       Impact factor: 91.245

8.  Effects of cigarette smoking on the long-term course of Crohn's disease.

Authors:  J Cosnes; F Carbonnel; L Beaugerie; Y Le Quintrec; J P Gendre
Journal:  Gastroenterology       Date:  1996-02       Impact factor: 22.682

9.  A comparison of budesonide with prednisolone for active Crohn's disease.

Authors:  P Rutgeerts; R Löfberg; H Malchow; C Lamers; G Olaison; D Jewell; A Danielsson; H Goebell; O O Thomsen; H Lorenz-Meyer
Journal:  N Engl J Med       Date:  1994-09-29       Impact factor: 91.245

10.  Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.

Authors:  G R Greenberg; B G Feagan; F Martin; L R Sutherland; A B Thomson; C N Williams; L G Nilsson; T Persson
Journal:  N Engl J Med       Date:  1994-09-29       Impact factor: 91.245

View more
  4 in total

1.  Elevated risk of opportunistic viral infection in patients with Crohn's disease during biological therapies: a meta analysis of randomized controlled trials.

Authors:  Xiaobing Wang; Feng Zhou; Junzhang Zhao; Rui Zhou; Meifang Huang; Jin Li; Wei Wang; Shufang Xu; Bing Xia
Journal:  Eur J Clin Pharmacol       Date:  2013-07-25       Impact factor: 2.953

2.  Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease.

Authors:  Kriszta Molnár; Adám Vannay; Beáta Szebeni; Nóra Fanni Bánki; Erna Sziksz; Aron Cseh; Hajnalka Győrffy; Péter László Lakatos; Mária Papp; András Arató; Gábor Veres
Journal:  World J Gastroenterol       Date:  2012-07-07       Impact factor: 5.742

3.  Hyperoxidation of ether-linked phospholipids accelerates neutrophil extracellular trap formation.

Authors:  Satoshi Yotsumoto; Yuito Muroi; Tatsuya Chiba; Rio Ohmura; Maki Yoneyama; Megumi Magarisawa; Kosuke Dodo; Naoki Terayama; Mikiko Sodeoka; Ryohei Aoyagi; Makoto Arita; Satoko Arakawa; Shigeomi Shimizu; Masato Tanaka
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

4.  Select a suitable treatment strategy for Crohn's disease: step-up or top-down.

Authors:  Qian-Qian Chen; Li Yan; Jun Wan
Journal:  EXCLI J       Date:  2014-02-13       Impact factor: 4.068

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.